Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Daohong Zhou
University of Florida, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Dialectic Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Daohong Zhou is a Professor in the Pharmacy Department. Dr. Zhou owns approximately (b)(4) of the stock in Dialectic Therapeutics, Inc. and is the Co-Principal Investigator for the company. Dr. Zhou’s research concerns the development of potential cancer therapies by targeting Bcl-2 proteins, which is related to patents that are licensed by Dialectic Therapeutics. Dialectic Therapeutics, Inc. is interested because the data generated from the proposed studies may directly benefit the drug development projects in the company. Therefore, Dialectic Therapeutics, Inc. can be affected by the research funded by NIH because of the data generated.
NCI Clinical and Translational Exploratory/ Developmental Studies
PROJECT NARRATIVE The proposed research employs an emerging drug discovery technology, PROTAC, coupled with an innovative concept of E3 ligase based tissue specific induction of target protein degradation, to overcome the dose-limiting thrombocytopenia associated with Bcl-2/Bcl-xL inhibitors. This could lead to a breakthrough in developing cancer therapies targeting Bcl-2 family proteins.
Filed on January 10, 2019.
Tell us what you know about Daohong Zhou's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Daohong Zhou”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Daohong Zhou | Univ of Arkansas for Med Scis | Conflict of Interest | Cenexys, Inc. | Value cannot be readily determined |
| Daohong Zhou | Univ of Arkansas for Med Scis | Conflict of Interest | Cenexys, Inc. | $40,000 - $59,999 |
| Daohong Zhou | Univ of Arkansas for Med Scis | Conflict of Interest | Cenexys, Inc. | $40,000 - $59,999 |
| Daohong Zhou | Univ of Arkansas for Med Scis | Conflict of Interest | Cenexys, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.